Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
NCT ID: NCT05427487
Last Updated: 2025-02-25
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
70 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-02-17
Study Completion Date
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a Phase 1 open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 as monotherapy and in combination with an immune checkpoint inhibitor in patients with advanced micro satellite-stable (MSS) colorectal cancer, or gastric or ovarian cancer.
The study is run in 2 parts. Phase 1a is dose escalation IVX037 monotherapy and Phase 1b is IVX037 with checkpoint inhibitor, sintilimab.
The study is run in 2 parts. Phase 1a is dose escalation IVX037 monotherapy and Phase 1b is IVX037 with checkpoint inhibitor, sintilimab.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC
NCT05438108
Metastatic Colorectal Cancer
UNKNOWN
PHASE2
Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer
NCT03186326
Metastatic Colorectal Cancer
MSI
COMPLETED
PHASE2
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
NCT03475953
Colorectal Cancer Not MSI-H or MMR-deficient
GIST
Oesophageal or Gastric Carcinoma
+12 more
RECRUITING
PHASE1/PHASE2
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
NCT05379595
Advanced or Metastatic Colorectal Cancer
RECRUITING
PHASE1/PHASE2
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
NCT03647839
Colorectal Cancer Metastatic
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In Phase 1a, participants are treated with IVX037 alone by intratumoral administration as monotherapy. Participants will be enrolled by cohort, with a Safety Review Committee (SRC) reviewing any dose-limiting toxicities (DLTs) that develop within 21 days after the first, second, or third dose of IVX037 for Cohorts 1, 2 and 3, respectively. Cohorts in the dose escalation will consist of 3-6 participants.
Participants in Cohort 3 are permitted to receive up to seven doses of IVX037 in the absence of DLTs and at the discretion of the Investigator. The SRC will review Cohort 3 safety data once three participants have completed three doses of IVX037 and 21-days of safety data is available and will make a recommendation as to whether the dose expansion phase may commence.
In the dose expansion phase, up to 5 additional participants from each of the three tumor types will be enrolled and receive IVX037 at the MTD. A total of fifteen (15) participants (5 from each of the 3 tumor types) at the maximum tolerated dose will provide paired tumor biopsies, one taken on Day 1 prior to IVX037 intratumoral injection and a second one taken two weeks later on Day 15.
In Part 1b, a total of 45 participants (15 from each of the three tumor types) will be enrolled and receive the number of intratumoral doses of IVX037 that were deemed safe during Part 1a, in combination with an intravenous (IV) immune checkpoint inhibitor, sintilimab. Sintilimab administration will commence on Study Day 8 and be administered every three weeks (Q3wks) at 200 mg/dose through to Study Day 344.
Participants in Cohort 3 are permitted to receive up to seven doses of IVX037 in the absence of DLTs and at the discretion of the Investigator. The SRC will review Cohort 3 safety data once three participants have completed three doses of IVX037 and 21-days of safety data is available and will make a recommendation as to whether the dose expansion phase may commence.
In the dose expansion phase, up to 5 additional participants from each of the three tumor types will be enrolled and receive IVX037 at the MTD. A total of fifteen (15) participants (5 from each of the 3 tumor types) at the maximum tolerated dose will provide paired tumor biopsies, one taken on Day 1 prior to IVX037 intratumoral injection and a second one taken two weeks later on Day 15.
In Part 1b, a total of 45 participants (15 from each of the three tumor types) will be enrolled and receive the number of intratumoral doses of IVX037 that were deemed safe during Part 1a, in combination with an intravenous (IV) immune checkpoint inhibitor, sintilimab. Sintilimab administration will commence on Study Day 8 and be administered every three weeks (Q3wks) at 200 mg/dose through to Study Day 344.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Colorectal Cancer
Gastric Cancer
Ovarian Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SEQUENTIAL
Phase 1 open-label, non-randomized, multi-center clinical trial. The study is run in 2 parts. Part 1a is dose escalation of IVX037 monotherapy. Part 1b is IVX037 with checkpoint inhibitor, sintilimab.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1a
IVX037 administered intratumorally, 1, 2 or 3 doses q2wks, Day 1, 15 and 29.
Group Type
EXPERIMENTAL
IVX037
Intervention Type
BIOLOGICAL
Bioselected oncolytic RNA virus
Part 1b
IVX037 administered intratumorally 3 doses q2wks, for up to 7 doses. Sintilimab administration will commence on Study Day 8 and be administered every three weeks (Q3wks) at 200 mg/dose through to Study Day 344.
Group Type
EXPERIMENTAL
IVX037
Intervention Type
BIOLOGICAL
Bioselected oncolytic RNA virus
Sintilimab
Intervention Type
BIOLOGICAL
An immune checkpoint inhibitor
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IVX037
Bioselected oncolytic RNA virus
Intervention Type
BIOLOGICAL
Sintilimab
An immune checkpoint inhibitor
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Has either a histologically confirmed advanced colorectal, gastric/gastroesophageal adenocarcinoma, or ovarian cancer that has progressed or is not suitable for standard of care systemic therapies. Participants with colorectal cancer must have either a primary tumor or a biopsy of a metastatic tumor which has been shown to lack microsatellite instability (by PCR) or to have normal expression of mismatch repair enzymes (by immunohistochemistry). That is, a mismatch repair proficient mCRC tumor.
2. Progressed on or after at least one prior line of systemic therapy and must not have had more than 3 prior lines. Phase 1b only: participants with gastroesophageal cancer must have failed prior treatment with an immune checkpoint inhibitor.
3. Has at least one injectable tumor that meets RECIST1.1 criteria to be designated as a target lesion, and is:
1. a liver lesion 1.0 to 6.5 cm (longest diameter) meeting RECIST criteria on baseline CT scan or MRI and suitable for injection under CT or ultrasound guidance, and participant has an estimated total tumor burden of disease \< 1/3 of liver volume based on CT or MRI imaging, or
2. A measurable lymph node, i.e., with a short axis diameter (SAD) of 1.5 cm to 6.5 cm, or
3. Other solid tumor with a longitudinal diameter 1.0 cm to 6.5 cm.
4. No other lesions (including non-injected lesions) greater than 6.5 cm (longest diameter).
Note (i): Only 2 target lesions may be designated in any one organ but if an organ such as the liver has more than 2 lesions which can be injected, the others, up to 3 additional, may be designated as NTLs and injected. Alternatively, target and non-target lesions elsewhere up to a total of 5 may be selected for injection.
Note (ii): Tumor lesions located in areas previously subjected to radiation or other locoregional therapies are not considered measurable unless there is a demonstrated progression in that lesion, as determined by the Investigator.
4. Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale.
5. Has demonstrated adequate organ function defined in the protocol, from samples collected within 72 hours prior to the start of treatment.
6. Is a male or female from 18 to 85 years or age at the time of signing the informed consent.
7. Must be willing to abstain from activities or use proper birth control methods for the duration of the study:
1. Female participants of child-bearing potential must be willing to use an adequate method of contraception. Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.
2. Male participants of child-bearing potential must agree to use an adequate method of contraception. Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.
8. The participant (or their legally acceptable representative if applicable) has provided written, informed consent prior to the initiation of any study procedures.
9. Female participants of child-bearing potential must have a negative urine pregnancy test within 72 hours prior to receiving the first dose of study medication. If a urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.
10. Participants must have fully recovered to NCI-CTCAE Grade 1 or better from AEs due to all previous anticancer therapies prior to entering this study. Note: Participants with Grade ≤ 2 AEs that are deemed not clinically significant by the Investigator may qualify for the study with approval by the Sponsor.
11. The participant has a life expectancy of greater than 6 months.
2. Progressed on or after at least one prior line of systemic therapy and must not have had more than 3 prior lines. Phase 1b only: participants with gastroesophageal cancer must have failed prior treatment with an immune checkpoint inhibitor.
3. Has at least one injectable tumor that meets RECIST1.1 criteria to be designated as a target lesion, and is:
1. a liver lesion 1.0 to 6.5 cm (longest diameter) meeting RECIST criteria on baseline CT scan or MRI and suitable for injection under CT or ultrasound guidance, and participant has an estimated total tumor burden of disease \< 1/3 of liver volume based on CT or MRI imaging, or
2. A measurable lymph node, i.e., with a short axis diameter (SAD) of 1.5 cm to 6.5 cm, or
3. Other solid tumor with a longitudinal diameter 1.0 cm to 6.5 cm.
4. No other lesions (including non-injected lesions) greater than 6.5 cm (longest diameter).
Note (i): Only 2 target lesions may be designated in any one organ but if an organ such as the liver has more than 2 lesions which can be injected, the others, up to 3 additional, may be designated as NTLs and injected. Alternatively, target and non-target lesions elsewhere up to a total of 5 may be selected for injection.
Note (ii): Tumor lesions located in areas previously subjected to radiation or other locoregional therapies are not considered measurable unless there is a demonstrated progression in that lesion, as determined by the Investigator.
4. Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale.
5. Has demonstrated adequate organ function defined in the protocol, from samples collected within 72 hours prior to the start of treatment.
6. Is a male or female from 18 to 85 years or age at the time of signing the informed consent.
7. Must be willing to abstain from activities or use proper birth control methods for the duration of the study:
1. Female participants of child-bearing potential must be willing to use an adequate method of contraception. Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.
2. Male participants of child-bearing potential must agree to use an adequate method of contraception. Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.
8. The participant (or their legally acceptable representative if applicable) has provided written, informed consent prior to the initiation of any study procedures.
9. Female participants of child-bearing potential must have a negative urine pregnancy test within 72 hours prior to receiving the first dose of study medication. If a urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required.
10. Participants must have fully recovered to NCI-CTCAE Grade 1 or better from AEs due to all previous anticancer therapies prior to entering this study. Note: Participants with Grade ≤ 2 AEs that are deemed not clinically significant by the Investigator may qualify for the study with approval by the Sponsor.
11. The participant has a life expectancy of greater than 6 months.
Exclusion Criteria
Medical Conditions
1. The potential participant is deemed to be a candidate for hepatic surgery or locoregional therapy for liver lesions with curative intent or requires other systemic anti-cancer therapy.
2. The participant has clinically significant ascites (Grade ≥2).
3. Participants with any other concurrent uncontrolled illness, including mental illness or substance abuse, which may interfere with the ability of the participant to cooperate and participate in the trial; other examples of such conditions would include unstable or uncontrolled hypertension, unstable angina, myocardial infarction or cerebrovascular accident within 6 months of study entry.
4. The participant requires continuous systemic treatment with either corticosteroids (\>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 4 weeks prior to the first dose of study treatment. Single doses of corticosteroids for prophylaxis of allergic reactions during imaging studies with contrast are allowed within 4 weeks of study treatment.
5. The participant has not fully recovered from any effects of major surgery without significant detectable infection. Surgeries that require general anesthesia must have been completed at least 2 weeks before first dose of IVX037.
6. Participants with bleeding diathesis due to underlying medical conditions or the use of anticoagulation medications that is unable to be reversed by medical treatment.
7. Participants with tumors that lie close to an airway, major blood vessel or spinal cord, which, in the opinion of the Investigator, could cause occlusion, compression, or erosion of the vital structures.
8. Participants with multi-focal miliary disease without critical target lesions. Prior/Concomitant Therapy
9. Participants who have been previously treated with an immune checkpoint inhibitor (e.g., an anti-CTLA-4, anti-PD-1 or anti-PD-L1) must have completed their last dose at least 28 days prior to Day 1 and have demonstrated progressive disease during or following the immune checkpoint inhibitor therapy. The participant must also have no medical history of immune mediated adverse events including infusion (hypersensitivity) reactions ≥ Grade 3 (CTCAE), with the exceptions of adequately treated hypothyroidism and type 1 diabetes mellitus (hyperglycemia) resulting from past treatment with an immune checkpoint inhibitor and non-exfoliative dermatologic reactions such as vitiligo. A history of Grade 2 immune-mediated infusion reactions to an immune checkpoint inhibitor while receiving adequate prophylactic treatment for hypersensitivity reactions is also exclusionary.
10. Participants who require prohibited treatments (i.e., non-protocol-specified anticancer pharmacotherapy, surgery, or radiotherapy for treatment of malignancy). Prohibited medications must be ceased at least 21 days or 5 half-lives (whichever is longer) prior to Day 1.
Prior/Concurrent Clinical Study Experience
11. Is currently participating and receiving other study therapy including an investigational agent or device within 4 weeks of Day 1.
12. Participants who have received a live vaccine within 4 weeks of the first day of planned IVX037 treatment or any other vaccine including killed virus and mRNA vaccines within 2 weeks of the first day of planned IVX037 treatment.
Diagnostic Assessments
13. Participant with active (i.e., symptomatic or growing) central nervous system (CNS) metastases. Participants with CNS metastases are eligible for the trial if the metastases have been treated by surgery and/or radiotherapy, the participant is off corticosteroids for at least 2 weeks prior to first dose of IVX037 and have stable disease on imaging for 3 months prior to Day 1.
14. Participant has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected). Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by the local health authority.
15. Participant has a severe infection or other uncontrolled active infectious disease requiring treatment that would interfere with the evaluation of safety and efficacy or is not in the best interest of the participant to participate, in the opinion of the treating Investigator.
16. Has a history of other malignancies within the previous 3 years, except for locally curable cancers which have been apparently cured such as basal cell or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix or breast or other cancers with low risk of recurrence in discussion with the Sponsor.
17. Has a history of drug-induced interstitial lung disease or non-infectious pneumonitis requiring steroids, except for those induced by radiation therapies.
18. Has a history of a prior organ transplantation, including allogenic stem-cell transplantation.
19. Has an active or known documented autoimmune disease within the past 2 years that has required systemic treatment.
20. Has a history of primary immunodeficiency.
21. Has an evidence of small bowel obstruction as determined by air/fluid levels on computed tomography (CT) scan, or recent hospitalization for small bowel obstruction within 3 months prior to starting trial treatment.
22. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator.
Other Exclusions
23. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the Screening visit through 120 days after the last dose of trial treatment.
1. The potential participant is deemed to be a candidate for hepatic surgery or locoregional therapy for liver lesions with curative intent or requires other systemic anti-cancer therapy.
2. The participant has clinically significant ascites (Grade ≥2).
3. Participants with any other concurrent uncontrolled illness, including mental illness or substance abuse, which may interfere with the ability of the participant to cooperate and participate in the trial; other examples of such conditions would include unstable or uncontrolled hypertension, unstable angina, myocardial infarction or cerebrovascular accident within 6 months of study entry.
4. The participant requires continuous systemic treatment with either corticosteroids (\>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 4 weeks prior to the first dose of study treatment. Single doses of corticosteroids for prophylaxis of allergic reactions during imaging studies with contrast are allowed within 4 weeks of study treatment.
5. The participant has not fully recovered from any effects of major surgery without significant detectable infection. Surgeries that require general anesthesia must have been completed at least 2 weeks before first dose of IVX037.
6. Participants with bleeding diathesis due to underlying medical conditions or the use of anticoagulation medications that is unable to be reversed by medical treatment.
7. Participants with tumors that lie close to an airway, major blood vessel or spinal cord, which, in the opinion of the Investigator, could cause occlusion, compression, or erosion of the vital structures.
8. Participants with multi-focal miliary disease without critical target lesions. Prior/Concomitant Therapy
9. Participants who have been previously treated with an immune checkpoint inhibitor (e.g., an anti-CTLA-4, anti-PD-1 or anti-PD-L1) must have completed their last dose at least 28 days prior to Day 1 and have demonstrated progressive disease during or following the immune checkpoint inhibitor therapy. The participant must also have no medical history of immune mediated adverse events including infusion (hypersensitivity) reactions ≥ Grade 3 (CTCAE), with the exceptions of adequately treated hypothyroidism and type 1 diabetes mellitus (hyperglycemia) resulting from past treatment with an immune checkpoint inhibitor and non-exfoliative dermatologic reactions such as vitiligo. A history of Grade 2 immune-mediated infusion reactions to an immune checkpoint inhibitor while receiving adequate prophylactic treatment for hypersensitivity reactions is also exclusionary.
10. Participants who require prohibited treatments (i.e., non-protocol-specified anticancer pharmacotherapy, surgery, or radiotherapy for treatment of malignancy). Prohibited medications must be ceased at least 21 days or 5 half-lives (whichever is longer) prior to Day 1.
Prior/Concurrent Clinical Study Experience
11. Is currently participating and receiving other study therapy including an investigational agent or device within 4 weeks of Day 1.
12. Participants who have received a live vaccine within 4 weeks of the first day of planned IVX037 treatment or any other vaccine including killed virus and mRNA vaccines within 2 weeks of the first day of planned IVX037 treatment.
Diagnostic Assessments
13. Participant with active (i.e., symptomatic or growing) central nervous system (CNS) metastases. Participants with CNS metastases are eligible for the trial if the metastases have been treated by surgery and/or radiotherapy, the participant is off corticosteroids for at least 2 weeks prior to first dose of IVX037 and have stable disease on imaging for 3 months prior to Day 1.
14. Participant has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \[qualitative\] is detected). Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by the local health authority.
15. Participant has a severe infection or other uncontrolled active infectious disease requiring treatment that would interfere with the evaluation of safety and efficacy or is not in the best interest of the participant to participate, in the opinion of the treating Investigator.
16. Has a history of other malignancies within the previous 3 years, except for locally curable cancers which have been apparently cured such as basal cell or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix or breast or other cancers with low risk of recurrence in discussion with the Sponsor.
17. Has a history of drug-induced interstitial lung disease or non-infectious pneumonitis requiring steroids, except for those induced by radiation therapies.
18. Has a history of a prior organ transplantation, including allogenic stem-cell transplantation.
19. Has an active or known documented autoimmune disease within the past 2 years that has required systemic treatment.
20. Has a history of primary immunodeficiency.
21. Has an evidence of small bowel obstruction as determined by air/fluid levels on computed tomography (CT) scan, or recent hospitalization for small bowel obstruction within 3 months prior to starting trial treatment.
22. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator.
Other Exclusions
23. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the Screening visit through 120 days after the last dose of trial treatment.
Minimum Eligible Age
18 Years
Maximum Eligible Age
85 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Innovent Biologics (Suzhou) Co. Ltd.
INDUSTRY
Sponsor Role
collaborator
ImmVirx Pty Ltd
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Darren Shafren
Role: STUDY_CHAIR
ImmVirx Pty Ltd
Oksana Zdanska
Role: STUDY_DIRECTOR
ImmVirx Pty Ltd
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sydney site
Sydney, New South Wales, Australia
Site Status
RECRUITING
South Australia site
Adelaide, South Australia, Australia
Site Status
RECRUITING
Melbourne Site
Melbourne, Victoria, Australia
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Australia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Oksana Zdanska
Role: primary
Oksana Zdanska
Role: primary
Oksana Zdanska
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Liu J., Tebbutt, N., Price, T., Hus, E., Al-Asady, R., Shafren, D., Zdanska, O., Croll, N., Wong, M. Phase 1a/b open-label, non-randomized, multi-centre clinical trial of intratumoral IVX037 alone and in combination with anti-PD1 in patients with advanced microsatellite stable (MSS) colorectal, gastroesophageal or ovarian cancer: trial in progress. Medical Oncology Group of Australia (MOGA) Sydney, Australia Conference Poster 2024
Reference Type
RESULT
Liu, J., Price, T., Tebbutt, N., Hsu, E., Al-Asady, R., Shafren, D., Croll, N., Wong, M. Phase 1a open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in patients with advanced microsatellite stable (MSS) colorectal, gastroesophageal or ovarian cancer. SITC 2023 Poster Presentation. Abstract Number 649
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CP-IVX001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849
NOT_YET_RECRUITING
PHASE3
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
NCT02563002
COMPLETED
PHASE3
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
NCT02788279
COMPLETED
PHASE3
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
NCT06973343
NOT_YET_RECRUITING
PHASE2
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
NCT04854434
TERMINATED
PHASE2
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
NCT02876224
COMPLETED
PHASE1
Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer
NCT03651271
COMPLETED
PHASE2
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
NCT03711058
COMPLETED
PHASE1/PHASE2
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
NCT03592641
TERMINATED
PHASE2
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
NCT05236972
RECRUITING
PHASE3
Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma
NCT07127497
ACTIVE_NOT_RECRUITING
PHASE2
Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate
NCT04262687
UNKNOWN
PHASE2
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
NCT07229846
NOT_YET_RECRUITING
PHASE2
Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC
NCT05239650
NOT_YET_RECRUITING
PHASE2
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
NCT05768503
RECRUITING
PHASE3
Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
NCT00012389
COMPLETED
PHASE3
Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）
NCT07007767
NOT_YET_RECRUITING
PHASE2
Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer
NCT06776757
RECRUITING
PHASE1/PHASE2
I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations
NCT02818725
COMPLETED
PHASE3
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT01075048
COMPLETED
PHASE1/PHASE2
Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer
NCT03608046
UNKNOWN
PHASE2
An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread
NCT03377361
COMPLETED
PHASE1/PHASE2
Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
NCT07106034
NOT_YET_RECRUITING
PHASE2
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
NCT03758781
COMPLETED
PHASE1
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
NCT03785873
COMPLETED
PHASE1/PHASE2